Oncotelic’s Deciparticle Platform Validated for IV Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with Sapu Nano, has announced a significant breakthrough: the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences that validates its proprietary Deciparticle(TM) nanoparticle platform. This platform was used to develop Sapu003, an investigational intravenous everolimus formulation currently in a Phase 1b clinical trial. The publication details the platform's formulation design, scalable cGMP manufacturing process, product stability, and preclinical performance, highlighting its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds. This is a critical advancement because many promising drug candidates suffer from poor solubility, limiting their clinical utility. The Deciparticle(TM) platform could unlock the potential of numerous hydrophobic drugs, expanding treatment options for patients.

The research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including other hydrophobic drug candidates. Sapu003 is being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors, assessing safety, pharmacokinetics, and preliminary antitumor activity in combination with exemestane. Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, is driving this innovation. The company's CEO, Dr. Vuong Trieu, has over 500 patent applications and 75 issued U.S. patents. Oncotelic also owns 45% of GMP Bio, a joint venture advancing its own pipeline, and develops PDAOAI, a proprietary AI platform for drug discovery and manufacturing. The company's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, further supports the platform's development. For more information, visit www.oncotelic.com.